Point taken, but the non-novel antibiotics work for their purpose, cure rates are high, and they will be profitable.
No. Resistance will appear must more rapidly in a derivative, which is why their used as a last line of defence and not in feedstock as previously suggested. They currently profitable, but depleting known classes.
Personally, I think they're a waste of limited resources, as do most other bacteriologists.